DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma

Information source: Heinrich-Heine University, Duesseldorf
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bladder Cancer

Intervention: paclitaxel (Drug); RAD001 (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Heinrich-Heine University, Duesseldorf

Official(s) and/or principal investigator(s):
Peter Albers, Professor, Principal Investigator, Affiliation: Heinrich-Heine-University, Department of Urology

Summary

This is a single arm open- label phase II- trial evaluating safety and efficacy of paclitaxel and RAD001 in patients with metastatic urothelial bladder cancer who failed prior platin-based systemic therapy.

Clinical Details

Official title: A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response rate

Secondary outcome:

Duration of response

Progression free survival

overall survival

safety profile of combination RAD001 and paclitaxel

Detailed description: The screening phase for checking eligibility and evaluation of the patient prior start of study treatment will last up to 21 days. Tumor histology must be predominant urothelial carcinoma and confirmed histological or cytological. Patients who meet the inclusion criteria will be treated with paclitaxel 175 mg/m2 every 3 weeks and RAD001 10 mg once daily. Each cycle will use the combination of paclitaxel 175 mg/m2 3-weekly with RAD001 10 mg daily starting at day 1 of a 21 days treatment cycle. Additional visits after day 1 are performed at day 8 and day 15 of each cycle Assessment of safety and toxicity will be performed at every visit. Patients will be treated until no signs of clinical or radiological progression are evident and the study treatment is well tolerated for a maximum of 6 cycles.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with histologically proven carcinoma of the urinary tract including urinary

bladder, ureter, renal pelvis and lower urinary tract. Urothelial carcinoma should be the predominant histology

- Confirmation of locally relapsed or metastatic disease by imaging. Measurable disease

according to RECIST- guidelines with ≥1 measurable lesion has to be evident.

- If bone is the only metastatic site a quantification of the target lesion(s) using

MRI is mandatory.

- Failure of prior platin- based chemotherapy

- Patients may have shown progressive disease within the first 3 months of

platin-based chemotherapy (primary failure) or progression within 3 months after the end of platin-based chemotherapy (early relapse)-Prior therapy with ≤ 4 chemotherapeutic drugs

- Patients with tumor relapse within 3 months after cystectomy in the neoadjuvant or

adjuvant setting are not eligible.

- ECOG performance status 0-2

- Adequate haematological, liver and renal functions.

- Neutrophil count > 1500/mm3, haemoglobin > 9 g/dl, platelets ≥ 100. 000/ mm3

- Serum bilirubin ≤ 1. 5 x ULN, ALT and AST ≤ 2. 5x ULN. Patients with known liver

metastases who have an AST and ALT ≤ 5x ULN.

- serum creatinine ≤ 2 x ULN.

- Women of childbearing potential must have a negative serum or urine pregnancy test

within 14 days prior to the first dose of study drug. Female subjects of childbearing potential must be using two acceptable methods of contraception, from the time of screening and for the duration of the study, through study completion and for 3 months following study completion

- Age > 18 years.

- Able to communicate well with the investigator, to understand and comply with the

requirements of the study. Understand and sign the written informed consent.

- Patients must give written informed consent

- No concurrent treatment with other experimental drugs or anti-cancer drugs

- Another distinguishable malignancy will be permitted

Exclusion Criteria:

- chemotherapy, radiation therapy or any other anticancer therapy within 4 weeks of the

first dose of study drug.

- Participation in any clinical investigation within 4 weeks prior to initial dosing.

- known hypersensitivity to RAD001 or other rapamycin analogs and paclitaxel or other

taxanes, or to its excipients.

- previously received RAD001, other mTOR inhibitors or taxanes or epothilones

- known metastasis of central nervous system.

- symptomatic pleural effusions or symptomatic ascites.

- wide field radiation therapy to up to ≥ 25% of the bone marrow within 4 weeks prior

therapy.

- intravenous radionuclide therapy, e. g. phosphorus (32P), strontium (89SrCl), rhenium

(186Re)or samarium (153Sm).

- Patients who have undergone major surgery within 4 weeks prior to starting study

drug,open biopsy, or significant traumatic injury, or who have not recovered from the side effects of any of the above.

- Chronic systemic treatment with corticosteroids corresponding to a prednisone

equivalent of > 10 mg daily. Patients receiving corticosteroids must be on a stable dose for ≥ 4 weeks prior to the first dose of RAD001. Topical or inhaled corticosteroids are permitted.

- Concomitant medication with strong CYP3A4- inhibitors or CYP3A4- inducers.

- active bleeding diathesis.

- Neuropathy > grade 1.

- any severe and/or uncontrolled medical conditions(unstable angina pectoris,

symptomatic congestive heart failure, myocardial infarction ≤ 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection,cirrhosis,chronic or persistent active hepatitis)

- severely impaired lung function as defined as spirometry and DLCO that is 50% of the

normal predicted value and/or O2 saturation ≤ 88% at rest on room air

- Uncontrolled diabetes

- Hepatic impairment with a Child-Pugh score >9

Locations and Contacts

Universitätsklinik Hamburg, Medizinische Klinik und Poliklinik Onkologie - Hämatologie, Hamburg 20246, Germany

Klinik für Urologie, Klinikum rechts der Isar der TU München, München, Bavaria 81675, Germany

Heinrich-Heine-University of Duesseldorf, Department of Urology, Duesseldorf, NRW 40225, Germany

Universitätsklinik Essen, Klinik für Urologie, Essen, NRW 45122, Germany

Klinik für Urologie, Universitätsklinikum Muenster, Muenster, NRW 48149, Germany

Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg, Saarland 66421, Germany

Additional Information

Starting date: July 2009
Last updated: March 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017